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INTRODUCTION 
The morbidity and mortality associated with severe 
sepsis remain unacceptably high, and for this reason in 
recent years there has been considerable interest in 
gaining a better understanding of the pathophysiology 
of sepsis with a view to developing new approaches to 
treatment based on modifying aberrant host responses. 
A very large number of strategies have been proposed 
and evaluated, and, not surprisingly, not all of them are 
of equal merit [l]. Like all new drugs, they must first 
show evidence of activity in in vitro tests, and then be 
screened, evaluated and assessed in a variety of different 
systems. Animal models of severe sepsis and shock have 
come in for considerable criticism because they have 
not been particularly successful in predicting which of 
these experimental agents would prove to be more 
effective in clinical trials. Of  course, there may be many 
reasons for this, many of them not related to the 
appropriateness of the animal model per se. Further- 
more, it is important to remember that trials of therapy 
are not the only raison d’ktre of these models: they are 
equally important in developing ideas about patho- 
genesis. Nevertheless, there have been difficulties and, 
in this paper, I shall discuss the various technical and 
conceptual problems that have emerged, and suggest a 
strategy for the future. 
PURPOSE 
It is important to remember that the purpose of the 
experiment will have an important influence on its 
design. In the modeling of sepsis, experiments designed 
to look at pathogenesis will probably differ from those 
designed to evaluate therapy. For instance, studies 
designed to evaluate the role of cytokines in mediating 
superantigen-mediated injury would reasonably use a 
purified or recombinant protein toxin as the ‘challenge’, 
while experiments intended to evaluate the potential 
therapeutic role of a novel anti-cytokine agent would 
more appropriately use a whole bacterial challenge and 
employ antibiotics as part of the regimen, in order to 
provide a more ‘realistic’ setting. 
Similar considerations will influence the choice of 
small or large animal model. For example, initial studies 
of a new therapeutic agent may be concerned simply 
with demonstrating an effect in vivo, and a simple, small 
animal model with a mortality endpoint may be most 
appropriate. Later, it may become important to define 
much more closely what effects the drug is having on, 
for example, hemodynamics, and for this purpose a 
larger, instrumented animal model may be better. In 
practice, of course, the choice ofwhich animal to study 
is often based on traditional practices, and ethical and 
economic considerations. This is especially evident in 
the case of models of endotoxemia, which frequently 
involve rodents. In fact, rodents are extremely resistant 
to endotoxin and must be given doses of lipopoly- 
saccharide (LPS) several orders of magnitude greater 
than would be effective in more sensitive species such as 
rabbits or even horses, yet rodents are very widely used. 
IMPORTANT VARIABLES 
As in any animal model, there are many critical 
experimental variables, as follows: 
endotoxin contamination; 
cytokine contamination; 
susceptibility of animal species to LPS; 
dose and route of challenge; 
LPS/protein versus live bacterial challenge; 
choice of bacterial strain; 
Gram-negative versus Gram-positive infection; 
choice of endpoint; 
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experimental design (e.g. factorial design); 
blinding of investigators; 
therapeutic regimen-dose, route, frequency, etc.; 
use of appropriate controls. 
Endotoxin contamination 
It  has been known for many years that small amounts 
of endotoxin can induce a phenomenon known as 
tolerance [2,3]. The mechanism is not entirely clear, 
but there is no doubt that it can markedly reduce 
the susceptibility of an animal to a subsequent LPS 
challenge. Clearly, this has the capability to confuse the 
interpretation of an experiment in which pretreatment 
with a potential therapeutic agent appears to confer 
protection, but which is instead due to trace endotoxin 
contamination [4]. 
Cytokine contamination 
A similar concern surrounds the finding that cytokmes 
can contaminate the hybridoma fluid in which mono- 
clonal antibodies are prepared [ 5 ] .  Once again, a false- 
positive result can be obtained if the appropriate 
controls are riot used. 
Susceptibility to LPS 
The major differences between species in their sensitivity 
to LPS were noted above. There are a number of ways 
of making rodents more sensitive to endotoxin; these 
include treatment with galactosamine [6], lead acetate 
[7] and mucin plus hemoglobin [8] .  The problem with 
all these approaches is that they inevitably make an 
artificial system yet more unrepresentative, and so limit 
the interpretation of the results. Another critical vari- 
able is the genetic makeup of the animal. Outbred 
strains are perhaps more ‘representative’, but inbred 
animals are more consistent in their results. Either may 
be used, depending on the purpose of the experiments, 
but this is surely a critically important variable. More 
prosaically, variations in sex, age, weight and nutritional 
status can have significant effects on the outcome. 
Dose and route of challenge 
There is no doubt that the route/source of infection has 
a major influence on the outcome, and the potential 
for benefit from cytokine-based therapies. The clearest 
example of this comes from the anti-TNF strategies: 
mice infected intravenously with Escherichia coli are 
readily protected by monoclonal anti-TNF [9], yet 
anti-TNF is not effective in experimental peritoneal 
infections [lo]. It is clearly important to evaluate any 
potential new agent against a variety of different 
infections in different sites. 
LPS versus live bacterial challenge 
While initial experiments might reasonably be done 
with chemically purified LPS, this will never substitute 
for live bacterial challenge. Indeed, there are sometimes 
unappreciated complications even with pure LPS. The 
degree of aggregation can vary considerably, depending 
on the environment and this in turn can have a 
significant effect on its biological activity [ l l ] .  
Choice of bacterial strain 
This too is a key issue. First, it is important to realize 
that many laboratory-adapted strains have lost key 
virulence determinants and hence may give misleading 
results [ 121. Even more importantly, investigators must 
not rely on experiments with just one strain, or even 
one genus. It  is extraordinary how often experiments 
are conducted with one or two strains of E. roli, for 
instance, and the results then extrapolated to Gram- 
negative infection in general. In fact (and not really 
surprisingly), when different bacteria are used, quite 
different results can be obtained [13]. 
Gram-negative versus Gram-positive infection 
The widespread belief that sepsis and septic shock 
represent a final common pathway of severe infection, 
whether it be initiated by Gram-negative or Gram- 
positive infection, plus the historical interest in endo- 
toxin, has led to much of the emphasis in experimental 
models of shock being focused on Gram-negative 
infection. It is increasingly clear that there are im- 
portant differences in both the pathogenesis and the 
responsiveness of these types of infection [ 141, and there 
is no doubt that both need to be investigated separately. 
Another aspect of this is the need to examine infections 
caused by intracellular bacteria such as Salmotzella and 
Listeria, although this will more usually be in the 
context of evaluating possible adverse events [ 151. 
Experimental design 
This is perhaps an area which is most in need of careful 
re-evaluation. It goes without saying that all animal 
experimentation should be done in such a way as to 
ensure that the minimum number of animals is used 
which will ensure a statistically significant conclusion 
to be drawn. In the case of small rodent models, this 
has often involved the use of LDso systems, but 
increasingly this method is regarded as a very blunt tool 
which is not acceptable to the regulatory authorities. 
In many cases, it is not necessary to use death as an 
endpoint and, indeed, it niay be more informative to 
ask what effect is being seen on organ failures such 
as coagulation or respiratory disease. Furthermore, 
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more sophisticated methodological approaches such as 
factorial design of the experiment can minimize animal 
use and generate additional information. Finally, it is 
clearly good practice for investigators to be blinded as 
to the treatment group whenever possible; this can be 
particularly important in models such as the Shwartzman 
reaction, which are notoriously observer-dependent. 
Variations in the therapeutic regimen 
The use of cytokines or cytokine-modifying agents in 
models of sepsis will need to take into account the 
biology of the model, in particular the time course over 
which the cytokine is elaborated and the compartment 
in which it is found. The timing and the route of 
administration are important variables which need to 
form part of the experimental design. 
Controls 
Every good experiment has appropriate controls, but it 
will be obvious from the foregoing that, in this field 
in particular, obsessive attention to ensuring that all 
appropriate controls are included is critical if useful 
results are to be obtained. Greisman and Johnston have 
recently produced a detailed review describing the 
many mechanisms which might operate to confer 
protection in animal models of infection [16]. 
CONCLUSIONS 
No single model can fulfill all the requirements of ‘a 
model of sepsis’. Investigators must decide the precise 
purpose of their experiments and then choose a system 
which best answers the questions. Furthermore, in the 
preclinical development of a novel therapeutic agent it 
is important to use a ‘portfolio’ of different models 
to ensure that a specific effect is not limited to just 
Gram-negative infections, or is not effective with focal 
infections, for instance. At this stage, we cannot be 
certain which models are ‘best’ (i.e. will most accurately 
predict the effect in patients). However, it is reason- 
able to suggest that therapeutic agents should be 
tested; 
in small animal lethality models; 
in small animal infection models, with more than one 
bacterial strain, to include both Gram-positive and 
Gram-negative organisms, both with and without 
antibiotics; 
in some large animal models (which may include 
limited primate studies). 
Some of these issues, and the implications for trial 
design, were discussed at a Consensus Conference held 
at the National Institutes of Health, and the results of 
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